1. Home
  2. CNTN vs HURA Comparison

CNTN vs HURA Comparison

Compare CNTN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canton Strategic Holdings Inc. Common Stock

CNTN

Canton Strategic Holdings Inc. Common Stock

HOLD

Current Price

$1.88

Market Cap

178.5M

Sector

Health Care

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.16

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
HURA
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.5M
160.5M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
CNTN
HURA
Price
$1.88
$2.16
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $8.04
AVG Volume (30 Days)
★ 735.7K
250.0K
Earning Date
11-11-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 88.10
47.93
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.41
52 Week High
$5.27
$3.43

Technical Indicators

Market Signals
Indicator
CNTN
HURA
Relative Strength Index (RSI) 42.22 59.70
Support Level $1.75 $2.06
Resistance Level $2.40 $2.22
Average True Range (ATR) 0.14 0.13
MACD -0.02 0.03
Stochastic Oscillator 27.07 92.86

Price Performance

Historical Comparison
CNTN
HURA

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: